Evidence map›Paper›PMID 35456572›Full record

ArticlePharmaceutics2022

Targeting Zika Virus with New Brain- and Placenta-Crossing Peptide-Porphyrin Conjugates.

Toni Todorovski, Diogo A Mendonça, Lorena O Fernandes-Siqueira, Christine Cruz-Oliveira, Giuseppina Guida, Javier Valle, Marco Cavaco, Fernanda I V Limas, Vera Neves, Íris Cadima-Couto and 5 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Research advances in peptide‒drug conjugates.Acta pharmaceutica Sinica. B · 2023
    Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 3 countries.

Toni TodorovskiDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain.ORCID 0000-0002-9168-2830
Diogo A MendonçaInstituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal.ORCID 0000-0001-8003-4662
Lorena O Fernandes-SiqueiraInstituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.
Christine Cruz-OliveiraInstituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal.ORCID 0000-0003-4838-0703
Giuseppina GuidaDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain.
Javier ValleDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain.
Marco CavacoInstituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal.ORCID 0000-0002-0938-9038
Fernanda I V LimasInstituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.
Vera NevesInstituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal.ORCID 0000-0002-2989-7208
Íris Cadima-CoutoInstituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal.
Sira DefausDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain.ORCID 0000-0002-3106-458X
Ana Salomé VeigaInstituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal.
Andrea T Da PoianInstituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.ORCID 0000-0002-3969-704X
Miguel A R B CastanhoInstituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal.ORCID 0000-0001-7891-7562
David AndreuDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain.ORCID 0000-0002-6317-6666
University of Lisbon · PTUniversitat Pompeu Fabra · ESUniversidade Federal do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viral disease outbreaks affect hundreds of millions of people worldwide and remain a serious threat to global health. The current SARS-CoV-2 pandemic and other recent geographically- confined viral outbreaks (severe acute respiratory syndrome (SARS), Ebola, dengue, zika and ever-recurring seasonal influenza), also with devastating tolls at sanitary and socio-economic levels, are sobering reminders in this respect. Among the respective pathogenic agents, Zika virus (ZIKV), transmitted by

Indexed as

antiviralsBBB shuttlesblood–brain barrierblood–placental barrierpeptide-drug conjugatesporphyrinsZika virus

Identifiers

PMID35456572
PMCPMC9032516
OpenAlexW4220762130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.